Verona Pharma plc Stock price London S.E.

Equities

VRP

GB00BYW2KH80

Biotechnology & Medical Research

Delayed London S.E. 12:35:15 2020-10-29 pm EDT 5-day change 1st Jan Change
55 GBX +5.77% Intraday chart for Verona Pharma plc +4.76% -11.29%
Sales 2024 * 24.87M 31.41M Sales 2025 * 118M 149M Capitalization 1.03B 1.3B
Net income 2024 * -75M -94.71M Net income 2025 * -24M -30.31M EV / Sales 2024 * 34 x
Net cash position 2024 * 184M 232M Net cash position 2025 * 146M 185M EV / Sales 2025 * 7.5 x
P/E ratio 2024 *
-27.3 x
P/E ratio 2025 *
-97.5 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 75.42%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 59 20-01-31
Director of Finance/CFO 61 20-02-29
Chief Tech/Sci/R&D Officer - 22-12-31
Members of the board TitleAgeSince
Director/Board Member 79 16-06-16
Director/Board Member 60 16-09-11
Chairman 69 14-11-30
More insiders
Verona Pharma Plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and selective, dual phosphodiesterase 3 and 4 (PDE3 and PDE4) inhibitor. This dual inhibition enables it to act as a bronchodilator and a non-steroidal anti-inflammatory agent . It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
16.09 USD
Average target price
33.14 USD
Spread / Average Target
+105.98%
Consensus
  1. Stock
  2. Equities
  3. Stock Verona Pharma plc
  4. Stock Verona Pharma plc - London S.E.